HER2 CAR-T cells exhibited significant anti-tumor activity in treating MB and effectively cleared xenografted tumors in a mouse model via both regional and intravenous administration, with the dose required for regional administration being significantly lower than that for intravenous. The gene discussed is ERBB2; the disease is neoplasm.